Robert C. Faulkner - 12 Mar 2024 Form 4 Insider Report for Science 37 Holdings, Inc.

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
13 Mar 2024, 17:18:19 UTC
Prior SEC filing
06 Feb 2024
Next SEC filing
19 Mar 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Robert C. Faulkner

Key filing fact

Robert C. Faulkner filed Form 4 for Science 37 Holdings, Inc. on 13 Mar 2024.

Key facts

  • This page summarizes Robert C. Faulkner's Form 4 filing for Science 37 Holdings, Inc..
  • 2 reported transactions and 1 derivative row are listed below.
  • Accepted by SEC: 13 Mar 2024, 17:18.

Change

  • Previous filing in this sequence was filed on 06 Feb 2024.
  • Current net transaction value: -$154,048.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

SNCE transaction

Common Stock

Disposition pursuant to a tender of shares in a change of control transaction

Transaction value
$154,048
Shares
-26,791
Change %
-100%
Price
$5.75
Shares after
0
Date
12 Mar 2024
Ownership
Direct
Footnotes
F1, F2, F4, F5

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

SNCE transaction Derivative

Stock Options (Right to Buy)

Disposed to Issuer

Transaction value
Shares
-2,068
Change %
-100%
Price
Shares after
0
Date
12 Mar 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
2,068
Exercise price
$201.00
Footnotes
F1, F3, F4, F5
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Section 16 status

Robert C. Faulkner is no longer subject to Section 16 filing requirements. Form 4 or Form 5 obligations may still apply in specific circumstances.

Explanation of responses 5 footnotes

Footnote F1

The reported securities were disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 28, 2024, among the Issuer, eMed, LLC, a Delaware limited liability company ("Parent"), and Marlin Merger Sub Corporation, a Delaware corporation and a wholly owned subsidiary of Parent ("Merger Sub"), pursuant to which Merger Sub completed a tender offer for all outstanding shares of the Issuer's common stock ("Common Stock") at a purchase price of $5.75 per share, without interest and subject to applicable withholding taxes (the "Offer Price"), which such tender offer expired on March 11, 2024. After completion of the tender offer, Merger Sub merged with and into the Issuer, effective as of March 12, 2024 (such date and time of such merger, the "Effective Time"). These shares of Issuer Common Stock were tendered for purchase pursuant to the tender offer.

Footnote F2

Each restricted stock unit represents a contingent right to receive one share of the Common Stock. Pursuant to the Merger Agreement, at the Effective Time, each restricted stock unit that was outstanding immediately prior to the Effective Time was cancelled and converted into the right to receive a cash payment (without interest and subject to any applicable tax withholding) equal to (A) the Offer Price, multiplied by (B) the number of shares of Common Stock subject to such restricted stock unit. This number includes 24,742 unvested restricted stock units.

Footnote F3

Pursuant to the Merger Agreement, at the Effective Time, each option to purchase shares of Common Stock that was outstanding and unexercised immediately prior to the Effective Time, whether or not vested, with a per share exercise price that was equal to or greater than the Offer Price was cancelled with no consideration payable in respect thereof.

Footnote F4

The securities were granted to Mr. Faulkner in connection with his service as a member of the Board of Directors of the Issuer. Mr. Faulkner, a managing director of Redmile Group, LLC ("Redmile"), was elected to the board of the Issuer as a representative of Redmile and its affiliates. Pursuant to the policies of Redmile, Mr. Faulkner held these securities as a nominee on behalf, and for the sole benefit, of Redmile and assigned all economic, pecuniary and voting rights in respect of the securities to Redmile. Mr. Faulkner has disclaimed beneficial ownership of the securities, and the filing of this Form 4 shall not be deemed an admission that Mr. Faulkner was the beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Footnote F5

The securities may also have been deemed beneficially owned by Jeremy Green as the principal of Redmile. Redmile and Mr. Green have disclaimed beneficial ownership of the securities except to the extent of their pecuniary interest therein, and this Form 4 shall not be deemed an admission that Redmile or Mr. Green was a beneficial owner of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

SEC remarks

Mr. Faulkner was elected to the board of directors of the Issuer as a representative of Redmile and its affiliates. As a result, Redmile and Mr. Green were directors by deputization for purposes of Section 16 of the Securities Exchange Act of 1934, as amended. Immediately prior to the Effective Time, pursuant to the terms of the Merger Agreement, Mr. Faulkner resigned as a director of the Company, effective as of the Effective Time. On December 8, 2023, the Issuer effected a reverse stock split of its Common Stock at a ratio of 1-for-20. As a result of the reverse stock split, the shares of Common Stock, and the exercise price and shares of the Common Stock underlying outstanding equity awards, have been adjusted accordingly versus any amounts previously reported by the Reporting Persons.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .